From The Economic Times · Vikas Dandekar · · 50s
Indian Pharma Risk Aversion
Indian pharma leaders say risk aversion blocks innovation, urging tech adoption for faster drug development.
In brief
Indian pharma leaders say risk aversion blocks innovation, urging tech adoption for faster drug development. Indian pharma companies face innovation delays due to risk aversion, with leaders calling for tech adoption to accelerate drug development. Originally reported by The Economic Times.
Pharma Risk Aversion
Indian pharmaceutical industry's risk aversion hinders innovation, requiring tech adoption for faster drug development.
“In pharma and biopharma, the pipeline is the lifeline”
Drug Pipeline Challenges
Only one or two out of 10 drug candidates reach final stages and commercial milestones.
Biocon's Progress
Biocon advanced an anti-cancer drug to Phase III clinical trials.
Regulatory Momentum
India's regulatory process is gaining momentum for faster drug approvals.
Sun Pharma Acquisition
Sun Pharma acquired US-based Organon for $11.75 billion to boost global innovative drug launches.
Future Innovation Strategy
Indian pharma companies need tech adoption to leapfrog global competitors and accelerate drug development.
What it means
Indian pharma companies face innovation delays due to risk aversion, with leaders calling for tech adoption to accelerate drug development.
